BriSTAR Immunotech
Company Details
Status: Private
Employees: 1-10
Location:
Toronto, Canada
Type:
sample
Technology:
sample
sample
sample
sample
About: Our team at BriSTAR Immunotech is dedicated to the development and commercialization of innovative T cell immunotherapy products for the treatment of cancer and viral infections with urgent unmet medical needs.
We leverage our proprietary STAR-T platform to engineer next-generation T cell therapies for treating hematological malignancies and solid tumors. The STAR-T platform combines the advantages of CAR-T (Chimeric Antigen Receptor T-Cell immunotherapy) and TCR-T (T Cell Receptor T-cell immunotherapy) to produce mono- or bi-specific T cell therapies.
The promising antitumor actions of STAR-T cell therapies include better antigen sensitivity and stronger tumor infiltration. These properties are critical for achieving better responses in cancer patients, especially in treating solid tumors.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
BriSTAR Immunotech | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.